Inhibikase Therapeutics IKT
NASDAQ IKT
$1.66 -0.05 (-2.92%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)

Updated

Inhibikase Therapeutics' Notes Payables was $248,911 in Q4 2021, up 485.2% from $42,534 a year earlier and unchanged from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021) Analysis & Trends

From Q4 2020 onward, Inhibikase Therapeutics has reported Notes Payables for 4 quarters.

  • In earlier years, Notes Payables was $42,534 in FY2020.
  • Quarterly Notes Payables has moved between $42,534 (Q4 2020) and $994,789 (Q1 2021) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Inhibikase Therapeutics 288.92 Mn -296.56 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 248,911.00
Sep 30, 2021 248,911.00
Mar 31, 2021 994,789.00
Dec 31, 2020 42,534.00
API Access

Inhibikase Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=IKT&period=max&api_key=YOUR_API_KEY